ES2068705T3 - Tratamiento de la enfermedad neoplastica con interleuquina-10. - Google Patents

Tratamiento de la enfermedad neoplastica con interleuquina-10.

Info

Publication number
ES2068705T3
ES2068705T3 ES92904687T ES92904687T ES2068705T3 ES 2068705 T3 ES2068705 T3 ES 2068705T3 ES 92904687 T ES92904687 T ES 92904687T ES 92904687 T ES92904687 T ES 92904687T ES 2068705 T3 ES2068705 T3 ES 2068705T3
Authority
ES
Spain
Prior art keywords
interleukin
treatment
neoplastic disease
neoplastic
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92904687T
Other languages
English (en)
Inventor
Paulo J M Vieira
Kevin W Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2068705T3 publication Critical patent/ES2068705T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

SE PREVE UN METODO PARA EL TRATAMIENTO DE TUMORES QUE COMPRENDE LA ADMINISTRACION AL PACIENTE DE UNA CANTIDAD EFECTIVA DE INTERLEUKIN-10.
ES92904687T 1991-01-16 1992-01-15 Tratamiento de la enfermedad neoplastica con interleuquina-10. Expired - Lifetime ES2068705T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64134791A 1991-01-16 1991-01-16

Publications (1)

Publication Number Publication Date
ES2068705T3 true ES2068705T3 (es) 1995-04-16

Family

ID=24571976

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92904687T Expired - Lifetime ES2068705T3 (es) 1991-01-16 1992-01-15 Tratamiento de la enfermedad neoplastica con interleuquina-10.

Country Status (18)

Country Link
EP (1) EP0567576B1 (es)
JP (1) JP3260368B2 (es)
KR (1) KR100207766B1 (es)
AT (1) ATE116550T1 (es)
AU (1) AU652030B2 (es)
CA (1) CA2100553A1 (es)
CZ (1) CZ282523B6 (es)
DE (1) DE69201128T2 (es)
DK (1) DK0567576T3 (es)
ES (1) ES2068705T3 (es)
FI (1) FI933193L (es)
GR (1) GR3015510T3 (es)
HK (1) HK192196A (es)
HU (1) HU218598B (es)
NO (1) NO310444B1 (es)
OA (1) OA09908A (es)
SK (1) SK279556B6 (es)
WO (1) WO1992012725A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106823A (en) * 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
KR0170037B1 (ko) * 1992-08-20 1999-02-01 에릭 에스. 딕커 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적 조성물
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
EP0740552A1 (en) * 1994-01-20 1996-11-06 Schering Corporation Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
CA2205572A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
WO2001005821A2 (en) * 1999-07-16 2001-01-25 Maria Teresa Bejarano Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
ES2957546T3 (es) 2008-12-17 2024-01-22 Merck Sharp & Dohme Producción de mono- y di-PEG-IL10; y usos
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3206713A4 (en) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
MX9203409A (es) * 1989-12-20 1992-07-01 Schering Corp Proteinas bcrfi como inhibidores de la gama interferona.

Also Published As

Publication number Publication date
FI933193A7 (fi) 1993-07-14
SK279556B6 (sk) 1998-12-02
OA09908A (en) 1994-09-15
HU9302066D0 (en) 1993-11-29
CZ141293A3 (en) 1994-01-19
DE69201128T2 (de) 1995-05-24
GR3015510T3 (en) 1995-06-30
NO932570L (no) 1993-07-15
HU218598B (hu) 2000-10-28
NO310444B1 (no) 2001-07-09
CZ282523B6 (cs) 1997-07-16
HUT69962A (en) 1995-09-28
FI933193A0 (fi) 1993-07-14
CA2100553A1 (en) 1992-07-17
AU1261792A (en) 1992-08-27
EP0567576A1 (en) 1993-11-03
SK74793A3 (en) 1995-03-08
EP0567576B1 (en) 1995-01-04
DK0567576T3 (da) 1995-06-12
NO932570D0 (no) 1993-07-15
ATE116550T1 (de) 1995-01-15
DE69201128D1 (de) 1995-02-16
JPH06504785A (ja) 1994-06-02
HK192196A (en) 1996-10-25
JP3260368B2 (ja) 2002-02-25
KR100207766B1 (ko) 1999-07-15
FI933193L (fi) 1993-07-14
WO1992012725A1 (en) 1992-08-06
AU652030B2 (en) 1994-08-11

Similar Documents

Publication Publication Date Title
AU549481B2 (en) Hair growing agent
NO932570L (no) Behandling av neoplastisk sykdom med interleukin-10
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
MX9203444A (es) Medicamentos.
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
ES2135046T3 (es) 2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos.
ES2093774T3 (es) Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ES2078507T3 (es) Medicinas y derivados de sulfonanilida.
IT1251838B (it) Uso della nimesulide nel trattamento della cataratta
ES2055314T3 (es) Tratamiento de disfuncion leucocitaria con gm-csf.
ES2125354T3 (es) Composicion a base de tandospirona o de sus analogos.
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
ES2019634B3 (es) Terapia con clorfeniramina.
ATE435023T1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
MX9206135A (es) Metodos
IT1224250B (it) Associzione del depiprazolo con la morfina
ES2073871T3 (es) Tiazolidin-2,4-dionas en el tratamiento de la hipertension.
AR005866A1 (es) Composicion farmaceutica antioxidante
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
MX9302929A (es) Derivados de tetrahidro y perhidroisoquinolina y medios terapeuticos que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567576

Country of ref document: ES